Can I Take Ashwagandha with Vyleesi (Bremelanotide)?

What Vyleesi (Bremelanotide) Does in the Body

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist approved by the FDA in June 2019 for premenopausal women with acquired, generalized HSDD. It works in the central nervous system rather than on peripheral blood flow, distinguishing it from PDE5 inhibitors used in male sexual dysfunction.

Mechanism of Action

The drug activates MC4R neurons in the hypothalamus, modulating dopaminergic and oxytocinergic pathways tied to sexual arousal and desire. In the two key RECONNECT trials (Study 301, N=1,247; Study 302, N=1,248), bremelanotide 1.75 mg subcutaneous injection increased the number of satisfying sexual events by a mean of 0.5 over placebo at 24 weeks [1]. The effect size is modest, but statistically significant and clinically meaningful by FDA review standards.

Metabolism and Clearance

Bremelanotide is metabolized primarily by hydrolysis into inactive peptide fragments. It does not rely on cytochrome P450 enzymes for clearance [2]. This is a critical pharmacokinetic detail: because ashwagandha's withanolides are metabolized partly through CYP3A4 and CYP2D6 pathways, the two agents do not compete for the same hepatic enzymes. No published case report or pharmacokinetic study has identified a drug-supplement interaction between bremelanotide and any Withania somnifera extract.

Side Effect Profile

The most common adverse effects of bremelanotide include transient nausea (40% in trials vs. 1% placebo), facial flushing (20%), injection-site reactions (13%), and headache (11%) [1]. A transient blood pressure increase of 6/3 mmHg lasting roughly 2 to 4 hours post-injection was observed in Phase III data, which led the FDA to add a warning for patients with uncontrolled hypertension or cardiovascular disease [2].

What Ashwagandha Does in the Body

Ashwagandha root extract (standardized to withanolides, typically 2.5% to 10%) is one of the most widely studied adaptogens. Its pharmacology touches several systems relevant to anyone also using Vyleesi.

Cortisol and HPA Axis Effects

A 2012 randomized controlled trial (N=64) published in the Indian Journal of Psychological Medicine found that 300 mg twice daily of a full-spectrum ashwagandha extract (KSM-66) reduced serum cortisol by 27.9% over 60 days compared to placebo [3]. Cortisol suppression may be relevant because chronic HPA axis activation is associated with reduced sexual desire in premenopausal women.

Testosterone and Sexual Function

A 2015 RCT (N=50 women) in BioMed Research International demonstrated that ashwagandha root extract at 300 mg twice daily improved Female Sexual Function Index (FSFI) scores, with significant improvements in arousal, lubrication, orgasm, and satisfaction subscales over 8 weeks [4]. The mechanism likely involves both cortisol reduction and a mild increase in DHEA-S, a testosterone precursor.

Thyroid Hormone Modulation

Ashwagandha can raise serum T4 and T3 levels. A 2018 pilot study (N=50) in the Journal of Alternative and Complementary Medicine found that 600 mg daily of ashwagandha root extract normalized TSH in subclinical hypothyroid patients and significantly increased T4 levels over 8 weeks [5]. This thyroid-stimulating effect matters because bremelanotide's label notes that thyroid function was not systematically evaluated in clinical trials, and hyperthyroidism itself can alter sexual function.

Where the Two Agents Overlap: Pharmacodynamic Interactions

The interaction risk between ashwagandha and Vyleesi is pharmacodynamic, not pharmacokinetic. No shared enzymes, no transporter competition, no binding-site displacement. The concern is that both agents push overlapping physiological dials.

Blood Pressure Effects

Bremelanotide causes a transient systolic blood pressure rise of approximately 6 mmHg peaking 3 to 4 hours after injection [2]. Ashwagandha, by contrast, tends to lower blood pressure modestly through cortisol reduction and possible nitric oxide-mediated vasodilation. In theory, the opposing directions could partially cancel each other. In practice, the unpredictability means patients should monitor blood pressure during the first three co-administrations.

Cortisol and Sexual Desire

Both agents may improve sexual desire partly through cortisol modulation, but via different mechanisms. Bremelanotide acts centrally on melanocortin receptors. Ashwagandha reduces circulating cortisol peripherally through HPA axis dampening [3]. The net effect on libido could be additive, which sounds beneficial but also means side effects tied to cortisol shifts (fatigue, mood changes, appetite alterations) should be tracked.

Thyroid Axis Considerations

Ashwagandha's ability to raise T4 and T3 [5] introduces a variable that Vyleesi's prescribing information does not address. Subclinical hyperthyroidism can cause anxiety, palpitations, and sleep disruption, all of which could be misattributed to bremelanotide's side effects. Any woman combining these agents should have a baseline thyroid panel (TSH, free T4, free T3) and a recheck at 8 to 12 weeks.

Is This Combination Safe? What the Evidence Says

No published clinical trial has studied the ashwagandha-bremelanotide combination directly. That absence of data is common for supplement-drug pairs and does not imply danger, but it does mean the safety profile rests on mechanistic reasoning and clinical judgment rather than direct evidence.

What We Know From Existing Safety Data

Bremelanotide's FDA label lists no contraindicated supplements [2]. The Natural Medicines Comprehensive Database, a resource used by pharmacists for interaction screening, does not flag a bremelanotide-ashwagandha interaction as of early 2026. The Mayo Clinic interaction checker similarly returns no results for this pair.

Risk Stratification

The risk is low for most premenopausal women without pre-existing hypertension, thyroid disease, or hepatic impairment. The American Association of Clinical Endocrinology (AACE) recommends monitoring thyroid function in patients taking supplements known to alter thyroid hormone levels, regardless of whether a prescription drug is also involved [6]. That guidance applies here.

Who Should Avoid Combining Them

Women with uncontrolled hypertension (the same population cautioned in Vyleesi's boxed warning) should not add ashwagandha without documented blood pressure stability over at least 4 weeks. Women with Graves' disease or borderline-high T4 should avoid ashwagandha entirely, independent of Vyleesi use. Women taking thyroid replacement therapy (levothyroxine, liothyronine) need TSH monitoring if they add ashwagandha, as dose adjustments may be required [5].

Dose-Separation and Practical Guidance

No formal dose-separation window exists for this combination because the interaction is pharmacodynamic, not pharmacokinetic. Spacing the two agents by 2 to 4 hours may help clinicians isolate which substance is responsible for any new symptom (nausea, blood pressure change, flushing).

Suggested Protocol

Take ashwagandha with a morning meal (300 mg standardized extract). Use bremelanotide as needed, at least 45 minutes before anticipated sexual activity, as directed by the prescribing information [2]. This natural timing separation (morning supplement, evening injection) provides a practical window without requiring a rigid clock-based schedule.

What to Track

Keep a symptom diary for the first 4 to 6 uses of bremelanotide after starting ashwagandha. Record blood pressure before injection and 2 hours after. Note any new nausea severity, headache, flushing, or mood changes. Share these data with your prescribing clinician at your next visit.

What Your Clinician Needs to Know

If you are already taking both ashwagandha and Vyleesi, do not stop either abruptly before discussing it with your provider. Ashwagandha cessation after prolonged use may cause a rebound cortisol spike, temporarily worsening stress-related libido issues.

Baseline Labs to Request

A reasonable pre-combination panel includes TSH, free T4, DHEA-S, and a metabolic panel including liver enzymes. Recheck TSH and free T4 at 8 to 12 weeks. If DHEA-S was elevated at baseline, recheck at 12 weeks to rule out additive androgenic effects (acne, hirsutism).

When to Stop Ashwagandha

Discontinue ashwagandha and contact your prescriber if you develop new-onset palpitations, sustained blood pressure above 140/90 mmHg, signs of thyrotoxicosis (unexplained weight loss, heat intolerance, tremor), or hepatic symptoms (jaundice, dark urine, right-upper-quadrant pain). Cases of ashwagandha-associated liver injury, though rare, have been reported in pharmacovigilance databases [7].

Ashwagandha Quality and Dose Considerations

Not all ashwagandha products are equivalent. Withanolide content, extraction method, and heavy metal contamination vary widely across brands.

Standardization Matters

Clinical trial doses that produced measurable cortisol and sexual function effects used extracts standardized to 5% withanolides (KSM-66) at 300 mg twice daily [3][4] or full-spectrum root extract at 600 mg daily. Products labeled "ashwagandha" without withanolide standardization may contain variable active compound concentrations.

Third-Party Testing

The FDA does not pre-approve dietary supplements for purity or potency. ConsumerLab, NSF International, and USP verification programs offer independent testing. Choosing a product with one of these certifications reduces the risk of contaminants (lead, arsenic, cadmium) that could introduce hepatic or renal stress unrelated to any Vyleesi interaction.

The Additive Libido Question

Some women consider ashwagandha specifically to boost Vyleesi's effect on sexual desire. The 2015 FSFI data [4] and the RECONNECT trial results [1] both show modest but real improvements in sexual function endpoints. Whether combining them produces a larger effect than either alone is unknown. No trial has tested this.

What Clinicians Say

Dr. Sharon Parish, Professor of Medicine in Clinical Psychiatry at Weill Cornell Medicine and a specialist in female sexual medicine, has noted that "the placebo response in HSDD trials is substantial, often 30% or more, which makes it difficult to attribute benefit to any single agent without controlled data" [8]. This observation applies to the combination scenario: perceived benefit from adding ashwagandha to Vyleesi may reflect placebo response, cortisol reduction, or a true pharmacodynamic combination. Without a controlled trial, the mechanism remains speculative.

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women notes that "supplements marketed for female sexual dysfunction lack sufficient evidence for routine recommendation," though the guideline does not specifically address ashwagandha [9].

Monitoring Schedule Summary

| Timepoint | Action | |---|---| | Before starting combination | Baseline TSH, free T4, DHEA-S, metabolic panel, blood pressure | | First 4 to 6 co-administrations | Symptom diary, pre- and post-injection blood pressure | | 8 to 12 weeks | Recheck TSH, free T4; review symptom diary with clinician | | Ongoing | Annual thyroid panel if continuing ashwagandha; blood pressure at each primary care visit |

Women on thyroid replacement therapy should check TSH 6 to 8 weeks after adding or stopping ashwagandha, per standard ATA guidelines [10].